KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Liabilities: 2018-2024

Historic Total Liabilities for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to $7.9 billion.

  • Royalty Pharma's Total Liabilities rose 24.96% to $9.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 billion, marking a year-over-year increase of 24.96%. This contributed to the annual value of $7.9 billion for FY2024, which is 25.13% up from last year.
  • According to the latest figures from FY2024, Royalty Pharma's Total Liabilities is $7.9 billion, which was up 25.13% from $6.3 billion recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Total Liabilities ranged from a high of $7.9 billion in FY2024 and a low of $6.1 billion during FY2020.
  • Moreover, its 3-year median value for Total Liabilities was $7.3 billion (2022), whereas its average is $7.2 billion.
  • Per our database at Business Quant, Royalty Pharma's Total Liabilities declined by 13.59% in 2023 and then increased by 25.13% in 2024.
  • Yearly analysis of 5 years shows Royalty Pharma's Total Liabilities stood at $6.1 billion in 2020, then grew by 18.66% to $7.3 billion in 2021, then climbed by 0.29% to $7.3 billion in 2022, then declined by 13.59% to $6.3 billion in 2023, then rose by 25.13% to $7.9 billion in 2024.